PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL.

Autor:	Oliveira MBDR; Universidade Federai do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.; Escola de Saúde do Exército, Rio de Janeiro, RJ, Brazil., Marques BC; Universidade Federai do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Matos RA; Escola de Saúde do Exército, Rio de Janeiro, RJ, Brazil., Fontenelle CRDC; Universidade Federai do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Mello FCQ; Universidade Federai do Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Paschoal MEM; Escola de Saúde do Exército, Rio de Janeiro, RJ, Brazil.
Jazyk:	angličtina
Zdroj:	Acta ortopedica brasileira [Acta Ortop Bras] 2018; Vol. 26 (6), pp. 388-393.
DOI:	10.1590/1413-785220182606201669
Abstrakt:	Introduction: Pathological fractures are frequent skeletal-related events among lung cancer patients, which result in high morbidity and decreased overall survival and make operative treatment decisions challenging. Objectives: To identify risk factors associated with the occurrence of pathological fractures in patients with lung cancer and to determine survival. Methods: We conducted a retrospective cohort study with 407 lung carcinoma patients diagnosed between 2006 and 2015. The prevalence of bone metastases and pathological fractures was calculated. Statistical analysis was conducted using a chi-squared test, and the odds ratio and 95% confidence interval were calculated. Overall survival was determined using the Kaplan-Meier method and differences were compared using the log-rank test. Results: The prevalence of bone metastases and pathological fractures was 28.2% (n = 115) and 19.1% (n = 22), respectively. Pathological fractures were more frequent among patients with bone metastases at the time of diagnosis of lung cancer (24.7% [n = 20] vs. 5.9% [n = 2]; p < 0.05). The median overall survival following the diagnosis of lung cancer, bone metastases, and pathological fracture was 6, 4, and 2 months, respectively. Conclusions: Pathological fracture was associated with synchronous bone metastases and overall survival times were considerably reduced. Level of Evidence IV, Case Series. Competing Interests: All authors declare no potential conflict of interest related to this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu